Citigroup upgraded shares of Insulet (NASDAQ:PODD – Free Report) from a neutral rating to a buy rating in a report released on Monday morning, MarketBeat Ratings reports. They currently have $265.00 price objective on the medical instruments supplier’s stock, down from their previous price objective of $273.00. PODD has been the subject of several other […]
Insulet (NASDAQ:PODD) Rating Lowered to Neutral at Robert W Baird theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Gateway Advisory LLC acquired a new stake in Insulet Co. (NASDAQ:PODD – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 549,887 shares of the medical instruments supplier’s stock, valued at approximately $550,000. Other large investors also recently bought […]
Equities researchers at StockNews.com began coverage on shares of Insulet (NASDAQ:PODD – Get Free Report) in a note issued to investors on Thursday. The firm set a “hold” rating on the medical instruments supplier’s stock. A number of other brokerages have also commented on PODD. Wells Fargo & Company cut their price target on Insulet […]
StockNews.com started coverage on shares of Insulet (NASDAQ:PODD – Free Report) in a research note released on Thursday. The brokerage issued a hold rating on the medical instruments supplier’s stock. PODD has been the topic of several other reports. JPMorgan Chase & Co. cut their price objective on shares of Insulet from $365.00 to $325.00 […]